The Effect of Hand Massage with Violet Oil on Pruritus Level and Quality of Life in Patients Receiving Hemodialysis Treatment

December 25, 2024 updated by: KEVSER ÇAĞLA GURLAŞ, TC Erciyes University

The Effect of Hand Massage with Violet Oil on Pruritus Level and Quality of Life in Patients

Itching is among the common problems in individuals receiving hemodialysis (HD) treatment. Research on the effects of aromatherapy on the symptoms seen in dialysis patients is increasing. Studies in the literature have found findings that aromatherapy reduces skin dryness and itching. This study was an experimental study with randomized intervention, placebo and control groups to determine the effect of a 7-minute massage with 2% violet oil on the hand on the non-fistula arm during the dialysis session, 3 times a week for six weeks, on the level of itching and quality of life in individuals receiving HD treatment. It was planned as. The project will be determined on individuals who are treated in 7 hemodialysis centers in a provincial center and whose itch severity scores are 3 or higher and who meet the inclusion criteria for the study.According to the results, patients who meet the inclusion criteria will be randomly assigned to intervention, placebo and control groups. Considering similar studies in the literature, the number of patients to be sampled was determined as 81 people in total, 27 per group, using the G Power program, provided that alpha = 0.05, power = 0.95 and effect size was 0.8165. Taking into account possible losses, randomization of at least 30 patients will be made to each group. Ethics committee approval and institutional permissions were obtained for the project. Verbal and written informed consent forms will be obtained from individuals. The data of the research will be collected between July 2024 and September 2024. If the required number of samples cannot be reached, the data collection process will be extended. In the study, data will be collected using the patient introduction form, 5 D Itch Scale, Kidney Disease Quality of Life Scale (KDQOLTM-36) and patient follow-up charts. In line with the massage application protocol, in addition to the treatment of patients with high itching scores, hand massage will be applied with violet oil to the individuals in the intervention group and jojoba oil to the placebo group.No action will be taken on the control group. IBM SPSS 24.0 Statistics and Turcosa programs will be used to evaluate the data. Power analysis effect size calculations will be made in the Turcosa program. It is planned to use descriptive (mean, percentage and standard deviation) and analytical statistics (Kolmogorov-Smirnov test, Kruskal-Wallis test, Wilcoxon signed rank test, Mann-Whitney Utest) in data analysis. In comparisons, a p value of <0.05 will be considered statistically significant.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Enrolling by invitation

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
90

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Kayseri, Turkey, 38000
        • Erciyes University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Those aged 18 and over,
  • willing to participate in the study
  • Receiving HD treatment in HD units for at least 6 months and 3 sessions per week,
  • Continuing dialysis treatment in the same institution,
  • Patients who do not develop allergic reactions such as skin irritation, redness, burning and itching after 30 minutes by applying two drops of the oils used in the study to the outer part of the arm.
  • There was no change in the treatment program during the study period,
  • Having an itch score of 3 or above on the 5-D Itch Scale,
  • Individuals who can understand and communicate with Turkish will be included in the research.

Exclusion Criteria:

  • Those who have any disease of the respiratory system,
  • Those who have any allergies to the essential oils to be used,
  • Having a skin lesion in the area to be massaged,
  • Patients who use other TIT methods during the treatment process will be excluded from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: hand massage with violet oil
Hand massage with violet oil during hemodialysis session 3 times a week for 6 weeks
Other: hand massage with violet oil
In this study, individuals receiving hemodialysis treatment will be massaged with 2% violet oil for 5-7 minutes on the hand on the non-fistula arm during the dialysis session, 3 times a week for six weeks.
Placebo Comparator: hand massage with placebo jojoba oil
Hand massage with jojoba oil during hemodialysis session 3 times a week for 6 weeks
Other: hand massage with jojoba oil
Hand massage with jojoba oil for hemodialysis patients 3 times a week for 6 weeks
No Intervention: control group
There will be no intervention

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
5D Itch Scale score
Time Frame: 6 weeks
Elman et al. It was developed by in 2010. The scale evaluates the duration, degree, course, distribution and problems caused by itching experienced in the last two weeks. The total score of the scale varies between the lowest score of 5 (no itching) and the highest score of 25 points (severe itching). Duration, degree, direction and disability of itching are scored between 1 and 5 points.
6 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Kidney Disease Quality of Life Short Form- KDQOLTM-36
Time Frame: 6 weeks
It was developed by Hays et al. in 1994 to evaluate the quality of life of individuals receiving dialysis treatment. The original form of the scale consists of 134 items. The scale was shortened to 36 items by the Kidney Disease Quality of Life Improvement Center.The KDQOLTM-36 scale, which evaluates the last month of patients, has 36 items consisting of 5 subscales. SF-12 physical dimension (questions 1,2,3,4,5 and 8), SF-12 mental dimension (questions 6,7,9,10,11 and 12), burden of kidney disease (questions 13-16). It consists of five subscales: questions), symptom list (questions 17-28), and the impact of kidney disease on daily life (questions 29-36). The Likert method was used when scoring each item in the scale. Scores on each dimension range from 0 to 100, with higher scores indicating better health-related quality of life.
6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
TC Erciyes University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 1, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 30, 2025

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 31, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 19, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 25, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 25, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 25, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 25, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
December 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • ErciyessaglıkU

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings